Month: May 2019

Novartis has powered Ayala Pharmaceuticals to a $30 million series B round. Ayala will use the cash to fund mid-phase development of pan-Notch inhibitor AL101 in adenoid cystic carcinoma (ACC).

Ayala is looking to lead the way for the country’s burgeoning biotech sector and take its gamma secretase inhibitors all the way through to Phase III.